

IN THE CLAIMS:

Please amend claims 1, 7, 12 and 33, cancel claims 4, 9-11, 15, 18, 36, 42, 43, 46, 49, 50, 52-54 and 56-58, and add new claim 59-91 as follows.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1. **(Currently amended)** A pyrogen-free composition comprising a plasmid comprising a nucleotide sequence that encodes an immunogen operably linked to regulatory elements and a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is ~~selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL R2, TRICK2, DR6, and Caspase ICE~~ and wherein said immunogen is a pathogen antigen selected from the group consisting of an influenza antigen, an HIV-1 antigen and an HSV antigen.

2-5. **(Canceled)**

6. **(Previously presented)** An injectable pharmaceutical composition comprising the pyrogen free composition of claim 1.

7. **(Currently amended)** A method of inducing cytotoxic T cell response in an individual against an immunogen comprising administering by intramuscular injection to said individual a ~~pyrogen-free~~ composition comprising a plasmid comprising a nucleotide sequence that encodes

an immunogen operably linked to regulatory elements and a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is ~~selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Fcγ, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE~~ and wherein said immunogen is a pathogen antigen.

8-11. (Canceled)

12. (Currently amended) A pyrogen-free composition comprising two plasmids: a first plasmid comprising a nucleotide sequence that encodes an immunogen operably linked to regulatory elements; and a second plasmid comprising a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is ~~selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Fcγ, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE~~ and wherein said immunogen is a pathogen antigen selected from the group consisting of an influenza antigen, an HIV-1 antigen and an HSV antigen.

13-16. (Canceled)

17. (Previously presented) An injectable pharmaceutical composition comprising the pyrogen free composition of claim 12.

18-32. (Canceled)

33. (Currently amended) A method of inducing cytotoxic T cell response in an individual against an immunogen comprising administering to said individual by intramuscular injection a composition comprising two plasmids: a first plasmid comprising a nucleotide sequence that encodes said immunogen operable linked to regulatory elements; and a second plasmid nucleic acid molecule comprising a nucleotide sequence that encodes an immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is ~~selected from the group consisting of: L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-2, ICAM-3, CD2, LFA3, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE~~ and wherein the immunogen is a pathogen antigen.

34-54. (Canceled)

55. (Previously presented) A method of claim 33 wherein said immunogen is a viral antigen.

56-58. (Canceled)

59. (New) The pyrogen-free composition of claim 1 wherein said immunogen is an influenza antigen.

60. (New) An injectable pharmaceutical composition comprising the composition of claim 59.

61. (New) The pyrogen-free composition of claim 1 wherein said immunogen is an HIV-1 antigen.

62. **(New)** An injectable pharmaceutical composition comprising the composition of claim 61.
63. **(New)** The pyrogen-free composition of claim 1 wherein said immunogen is an HSV antigen.
64. **(New)** An injectable pharmaceutical composition comprising the composition of claim 63.
65. **(New)** The method of claim 7 wherein said composition is pyrogen free.
66. **(New)** The method of claim 7 wherein said immunogen is a viral antigen.
67. **(New)** The method of claim 66 wherein said composition is pyrogen free.
68. **(New)** The method of claim 7 wherein the immunogen is selected from the group consisting of: an influenza antigen, an HIV-1 antigen and an HSV antigen.
69. **(New)** The method of claim 68 wherein said composition is pyrogen free.
70. **(New)** The method of claim 7 wherein said immunogen is an influenza antigen.
71. **(New)** The method of claim 70 wherein said composition is pyrogen free.
72. **(New)** The method of claim 7 wherein said immunogen is an HIV-1 antigen.
73. **(New)** The method of claim 72 wherein said composition is pyrogen free.
74. **(New)** The method of claim 7 wherein said immunogen is a HSV antigen.

75. **(New)** The method of claim 74 wherein said composition is pyrogen free.
76. **(New)** The pyrogen-free composition of claim 12 wherein said immunogen is an influenza antigen.
77. **(New)** An injectable pharmaceutical composition comprising the composition of claim 76.
78. **(New)** The pyrogen-free composition of claim 12 wherein said immunogen is an HIV-1 antigen.
79. **(New)** An injectable pharmaceutical composition comprising the composition of claim 78.
80. **(New)** The pyrogen-free composition of claim 12 wherein said immunogen is an HSV antigen.
81. **(New)** An injectable pharmaceutical composition comprising the composition of claim 80.
82. **(New)** The method of claim 33 wherein said composition is pyrogen free.
83. **(New)** The method of claim 55 wherein said composition is pyrogen free.
84. **(New)** The method of claim 33 wherein the immunogen is selected from the group consisting of: an influenza antigen, an HIV-1 antigen and an HSV antigen.
85. **(New)** The method of claim 86 wherein said composition is pyrogen free.
86. **(New)** The method of claim 86 wherein said immunogen is an influenza antigen.

87. **(New)** The method of claim 88 wherein said composition is pyrogen free.
88. **(New)** The method of claim 86 wherein said immunogen is an HIV-1 antigen.
89. **(New)** The method of claim 90 wherein said composition is pyrogen free.
90. **(New)** The method of claim 86 wherein said immunogen is a HSV antigen.
91. **(New)** The method of claim 90 wherein said composition is pyrogen free.